Lilly hikes revenue forecasts on booming obesity drug sales

Group 1 - Eli Lilly is focusing on strengthening its leadership in the GLP-1 medicine market, which is projected to exceed $100 billion in the next decade [3] - The company's stock performance has remained relatively stable over the past year, despite mixed results from Zepbound and Mounjaro, and competition from Novo Nordisk [4] - Lilly is differentiating its products by demonstrating that Zepbound may outperform Novo's Wegovy in weight loss studies and is investing in production capabilities to avoid past manufacturing issues [5] Group 2 - Tirzepatide, marketed as Zepbound and Mounjaro, became the best-selling drug globally in Q3, contributing to a significant revenue increase for Lilly [7] - Combined sales of Zepbound and Mounjaro reached $10.1 billion in Q3, a substantial rise from $4.37 billion in the same period last year [7] - Lilly has raised its full-year revenue forecast to between $63 billion and $63.5 billion, up from a previous estimate of $60 billion to $62 billion, with earnings per share expected to increase as well [7][6]